Researchers have developed a new technique for tracking cancer by identifying personalized biomarkers from tumor DNA.
Announced Thursday during the 2010 AAAS Annual Meeting in San Diego, the findings show that next-generation sequencing technology is poised become an important tool in the new era of personalized management of cancer patients.
The results will be published in the 24 February 2010 issue of the journal Science Translational Medicine, published by AAAS.
"There is currently no test for cancer patients that provides personalized biomarkers for clinical management of disease, and we feel that this is an important step in bringing new genome sequencing technologies to personalized patient care," said senior author Victor Velculescu, associate professor of oncology and Co-Director of the Cancer Biology Program at Johns Hopkins.
Keeping cancer cells under control requires the ability to monitor residual and recurrent tumors in order to assess whether or not treatment is working. Based on discovering cancer-related changes in DNA, the Personalized Analysis of Rearranged Ends (PARE) approach provides a highly accurate and specific way to monitor tumors, by searching for the genetic bread-crumb trail left by lingering cancer cells after surgery or during drug therapy.
"We believe that this is one of the first applications of new genome sequencing technologies that could be useful for cancer patients," said Velculescu.
A nearly universal feature of human cancer is the widespread rearrangement of DNA. Yet historically, it has been difficult to accurately map such changes in individual tumors. Now, Velculescu and a team of colleagues from Johns Hopkins University and Life Technologies Corporation have used PARE to identify a handful of rearranged DNA sequences in four colorectal and two breast tumors.
Since these rearranged sequences are not present in normal DNA (only in tumor DNA), the researchers were able to create personalized biomarkers or "red flags" based on these unique sequences.
They used the biomarkers to hunt down tiny amounts of tumor DNA meshed within large quantities of normal DNA in blood and other bodily fluid samples--as could easily be done following surgical removal of tumors or other therapies.
"PARE uses genetic characteristics unique to the tumor to monitor disease progression. By exploiting rearrangements specific to the patient's tumor, we have developed a personalized approach for detection of residual disease," said co-author Rebecca Leary, graduate student at the Johns Hopkins Kimmel Cancer Center.
Granted, PARE is expensive—a tough barrier to cross in the shift towards broad clinical application. Nonetheless, this approach may profoundly alter how the effectiveness of cancer treatments like radiation, chemotherapy, and surgery are assessed in individual patients.
"As PARE becomes affordable, it will be a helpful addition for physicians to tailor patient care and may become a useful supplement to traditional monitoring by imaging or other approaches," said Leary.